A miR-1231 binding site polymorphism in the 3'UTR of IFNAR1 is associated with hepatocellular carcinoma susceptibility

Gene

Volumn 507, Issue 1, 2012, Pages 95-98

  Zhou, Chunxiao ^a   Yu, Qiang ^a   Chen, Lei ^a   Wang, Jian ^b   Zheng, Shudan ^a   Zhang, Jinkun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Department of Medical Oncology   (China)

Author keywords

Hepatocellular carcinoma; IFNAR1; Rs17875871; Susceptibility

Indexed keywords

ALPHA BETA OMEGA INTERFERON RECEPTOR 1; HEPATITIS B SURFACE ANTIGEN; INTERFERON; MICRORNA; MICRORNA 1231; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE DELETION; GENE INSERTION; GENE LOCATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL;

3' UNTRANSLATED REGIONS; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTOR, INTERFERON ALPHA-BETA;

HEPATITIS B VIRUS;

EID: 84864974809     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.06.073     Document Type: Article

References (27)

1. Allen R.C., Graves G., Budowle B. Polymerase chain reaction amplification products separated on rehydratable polyacrylamide gels and stained with silver. Biotechniques 1989, 7:736-744.
2. Ambrus J.L., et al. Free interferon-alpha/beta receptors in the circulation of patients with adenocarcinoma. Cancer 2003, 98:2730-2733.
3. Bellodi-Privato M., et al. Differential gene expression profiles of hepatocellular carcinomas associated or not with viral infection. Braz. J. Med. Biol. Res. 2009, 42:119-127.
4. Bosch F.X., Ribes J., Díaz M., Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
5. Buckland P.R., Coleman S.L., Hoogendoorn B., Guy C., Smith S.K., O'Donovan M.C. A high proportion of chromosome 21 promoter polymorphisms influence transcriptional activity. Gene Expr. 2004, 11:233-239.
6. Chen K., Song F., Calin G.A., Wei Q., Hao X., Zhang W. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis 2008, 29:1306-1311.
7. Damdinsuren B., et al. Interferon alpha receptors are important for antiproliferative effect of interferon-alpha against human hepatocellular carcinoma cells. Hepatol. Res. 2007, 37:77-83.
8. de Weerd N.A., Samarajiwa S.A., Hertzog P.J. Type I interferon receptors: biochemistry and biological functions. J. Biol. Chem. 2007, 282:20,053-20,057.
9. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
10. Elsharkawy A.M., Mann D.A. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 2007, 46:590-597.
11. Gomaa A.I., Khan S.A., Toledano M.B., Waked I., Taylor-Robinson S.D. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J. Gastroenterol. 2008, 14:4300-4308.
12. He X.X., et al. Persistent effect of IFNAR-1 genetic polymorphism on the long-term pathogenesis of chronic HBV infection. Viral Immunol. 2010, 23:251-257.
13. John B., Enright A.J., Aravin A., Tuschl T., Sander C., Marks D.S. Human microRNA targets. PLoS Biol. 2004, 2:e363.
14. Llovet J.M., et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000, 31:54-58.
15. Miyake K., et al. Serum evaluation of soluble interferon-a/b receptor and high-sensitivity C-reactive protein for diagnosis of the patients with gastrointestinal and hepatobiliary-pancreatic cancer. Cytokine 2009, 49:251-255.
16. Nault J.C., Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin. Liver Dis. 2011, 31:173-187.
17. Obi S., et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006, 106:1990-1997.
18. Oie S., et al. The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha. Int. J. Oncol. 2006, 29:1469-1478.
19. Patt Y.Z., et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J. Clin. Oncol. 2003, 21:421-427.
20. Song le H., et al. Association of two variants of the interferon-alpha receptor-1 gene with the presentation of hepatitis B virus infection. Eur. Cytokine Netw. 2008, 19:204-210.
21. Tanaka M., et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J. Epidemiol. 2011, 21:401-416.
22. Thorgeirsson S.S., Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 2002, 31:339-346.
23. Yu Q., Zhou C.X., Chen N.S., Zheng S.D., Shen L.M., Zhang J.K. A polymorphism within ErbB4 is associated with risk for hepatocellular carcinoma in Chinese population. World J. Gastroenterol. 2012, 18:383-387.
24. Zhang Q., et al. Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway. J. Virol. 2012, 86:1544-1554.
25. Zhou J., et al. Polymorphisms of type I interferon receptor 1 promoter and their effects on chronic hepatitis B virus infection. J. Hepatol. 2007, 46:198-205.
26. Zhou J., et al. Functional dissection of an IFN-alpha/beta receptor 1 promoter variant that confers higher risk to chronic hepatitis B virus infection. J. Hepatol. 2009, 51:322-332.
27. Zhou J., et al. A non-synonymous single nucleotide polymorphism in IFNAR1 affects susceptibility to chronic hepatitis B virus infection. J. Viral Hepat. 2009, 6:45-52.